UCB And 5 Other Stocks Have Very High Payout Ratio

(VIANEWS) – ELEC.STRASBOURG (ELEC.PA), SWORD GROUP (SWP.PA), ABC ARBITRAGE (ABCA.PA) are the highest payout ratio stocks on this list.

Here’s the data we’ve collected of stocks with a high payout ratio so far. The payout ratio in itself isn’t a promise of a future good investment but it’s an indicator of whether dividends are being paid and how the company chooses to distribute them.

When investigating a potential investment, the dividend payout ratio is a good statistic to know so here is a list of some companies with an above 30% payout ratio.

1. ELEC.STRASBOURG (ELEC.PA)

106.54% Payout Ratio

Électricite de Strasbourg Société Anonyme engages in the supply of electricity and natural gas to individuals, businesses, and local authorities in France. It is also involved in the design, construction, and operation of electrical engineering, industrial, and public lighting facilities, as well as heating networks; provision of collective catering engineering and energy renovation services; and technical management and optimization of energy installations. The company was founded in 1899 and is based in Strasbourg, France. Électricite de Strasbourg Société Anonyme is a subsidiary of EDF Développement Environnement SA.

Earnings Per Share

As for profitability, ELEC.STRASBOURG has a trailing twelve months EPS of €5.44.

PE Ratio

ELEC.STRASBOURG has a trailing twelve months price to earnings ratio of 16.14. Meaning, the purchaser of the share is investing €16.14 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 10.05%.

More news about ELEC.STRASBOURG.

2. SWORD GROUP (SWP.PA)

86.88% Payout Ratio

Sword Group S.E. provides IT and digital transformation services in Europe, the United States, the Oceania, and Asia. The company provides information systems integration and engineering services, including strategic and operational consulting, solution engineering and application development, project ownership support and project management support, infrastructure management and application maintenance for third parties, and resource outsourcing. Its products include Sword Phusion, an engineering information management software; Sword Tell, a CAD software for watch manufacturers and other industry sectors; Sword Venue, an event planning, collaboration, and organization software; and Sword Aequos that helps organizations to focus on their main business by implementing optimal collaborative tools and solutions supporting their day-to-day reality. The company serves banking and insurance, finance, industry, energy, public services, health, telco, government, and other markets. Sword Group S.E. was founded in 2000 and is headquartered in Windhof, Luxembourg.

Earnings Per Share

As for profitability, SWORD GROUP has a trailing twelve months EPS of €11.43.

PE Ratio

SWORD GROUP has a trailing twelve months price to earnings ratio of 3.6. Meaning, the purchaser of the share is investing €3.6 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 112.09%.

Revenue Growth

Year-on-year quarterly revenue growth grew by 21.3%, now sitting on 272.26M for the twelve trailing months.

Yearly Top and Bottom Value

SWORD GROUP’s stock is valued at €41.20 at 12:10 EST, way under its 52-week high of €53.00 and way higher than its 52-week low of €35.10.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on May 2, 2023, the estimated forward annual dividend rate is 1.7 and the estimated forward annual dividend yield is 4.36%.

More news about SWORD GROUP.

3. ABC ARBITRAGE (ABCA.PA)

81.63% Payout Ratio

ABC arbitrage SA, together with its subsidiaries, engages in the development of arbitrage strategies for liquid assets worldwide. It develops liquidity, statistical, risk, and derivatives arbitrage strategies; and provides asset and portfolio management services. The company was incorporated in 1995 and is based in Paris, France.

Earnings Per Share

As for profitability, ABC ARBITRAGE has a trailing twelve months EPS of €0.49.

PE Ratio

ABC ARBITRAGE has a trailing twelve months price to earnings ratio of 12.06. Meaning, the purchaser of the share is investing €12.06 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 18.12%.

Moving Average

ABC ARBITRAGE’s worth is under its 50-day moving average of €6.09 and under its 200-day moving average of €6.41.

Revenue Growth

Year-on-year quarterly revenue growth grew by 2.6%, now sitting on 61.44M for the twelve trailing months.

Sales Growth

ABC ARBITRAGE’s sales growth for the current quarter is 5.2%.

More news about ABC ARBITRAGE.

4. UCB (UCB.BR)

60.47% Payout Ratio

UCB SA, a biopharmaceutical company, develops products and solutions for people with neurology and immunology diseases. The company's primary products include Cimzia for inflammatory TNF mediated diseases, as well as ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Vimpat, Keppra, and Briviact for epilepsy; Neupro for Parkinson's disease and restless legs syndrome; Nayzilam, a nasal spray rescue treatment for epilepsy seizure clusters; and Zyrtec and Xyzal for allergies. It also offers Evenity for the treatment of osteoporosis in postmenopausal women; BIMZELX for treating psoriasis, psoriatic arthritis, axial spondyloarthritis, and hidradenitis suppurativa; and dapirolizumab pegol for systemic lupus erythematosus. In addition, the company is involved in developing rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; zilucoplan to treat myasthenia gravis and immune-mediated necrotizing myopathy; staccato alprazolam to treat tereotypical prolonged seizure; Bepranemab to treat Alzheimer's disease; and UCB0599 to treat Parkinson's disease. Further, it engages in contract manufacturing activities. UCB SA has collaboration agreements with Amgen, Biogen, Roche/Genentech, Novartis, Otsuka, and doc.ai. It operates in the United States, Japan, Germany, rest of Europe, Spain, France, China, Italy, the United Kingdom, Ireland, Belgium, and internationally. The company was incorporated in 1925 and is headquartered in Brussels, Belgium.

Earnings Per Share

As for profitability, UCB has a trailing twelve months EPS of €2.14.

PE Ratio

UCB has a trailing twelve months price to earnings ratio of 39.54. Meaning, the purchaser of the share is investing €39.54 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.81%.

Dividend Yield

As stated by Morningstar, Inc., the next dividend payment is on Apr 28, 2023, the estimated forward annual dividend rate is 1.33 and the estimated forward annual dividend yield is 1.59%.

Sales Growth

UCB’s sales growth for the current quarter is negative 5.1%.

Moving Average

UCB’s value is under its 50-day moving average of €84.76 and higher than its 200-day moving average of €77.62.

Yearly Top and Bottom Value

UCB’s stock is valued at €84.62 at 12:10 EST, under its 52-week high of €88.80 and way higher than its 52-week low of €66.62.

More news about UCB.

5. HEINEKEN (HEIA.AS)

31.4% Payout Ratio

Heineken N.V. brews and sells beer and cider in Europe, Americas, Africa, the Middle East, Eastern Europe, and the Asia Pacific. The company also provides soft drinks and water. It offers its beers under the Heineken, Amstel, Sol, Tiger, Birra Moretti, Pure Piraña, Desperados, Edelweiss, and Lagunitas brands; and cider under the Strongbow Apple Ciders, Orchard Thieves, Cidrerie Stassen, Bulmers, and Old Mout brands, as well as under regional and local brands. The company offers its products to retailers, wholesalers, cafes, bars, pubs, hotels, and restaurants. Heineken N.V. was founded in 1864 and is headquartered in Amsterdam, the Netherlands. Heineken N.V. operates as a subsidiary of Heineken Holding N.V.

Earnings Per Share

As for profitability, HEINEKEN has a trailing twelve months EPS of €4.6.

PE Ratio

HEINEKEN has a trailing twelve months price to earnings ratio of 20.37. Meaning, the purchaser of the share is investing €20.37 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.6%.

More news about HEINEKEN.

6. HEINEKEN HOLDING (HEIO.AS)

31.33% Payout Ratio

Heineken Holding N.V., through its subsidiaries, engages in brewing and selling beer and cider in the Netherlands and internationally. The company's portfolio consists of approximately 300 international, regional, local, and specialty beers and ciders. The company was founded in 1864 and is based in Amsterdam, the Netherlands. Heineken Holding N.V. is a subsidiary of L'Arche Green N.V.

Earnings Per Share

As for profitability, HEINEKEN HOLDING has a trailing twelve months EPS of €4.63.

PE Ratio

HEINEKEN HOLDING has a trailing twelve months price to earnings ratio of 17.14. Meaning, the purchaser of the share is investing €17.14 for every euro of annual earnings.

The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.6%.

More news about HEINEKEN HOLDING.

Leave a Reply

Your email address will not be published. Required fields are marked *